Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Merger or Acquisition (May 2018)
23 slides from Myriad Genetics's merger presentation, May 29, 2018
Slide 1: Myriad Genetics Acquisition of Counsyl, Inc.
Myriad Genetics Acquisition of Counsyl, Inc. 05/29/2018 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: Strategic Rationale and Transaction Consideration
Myriad Genetics Acquisition of Counsyl, Inc. Strategic Rationale Entry into high-growth reproductive testing market Comprehensive women’s health product offering Broad reimbursement coverage with potential for further expansion Potential for revenue synergies by tripling reproductive testing reach P
Slide 4: Strategic Rationale 1+1=3
Strategic Rationale 1+1=3 Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com. Entry into high-growth reproductive testing market Comprehensive women’s health product offering Broad reimbursement with potential for future expansion Potential for revenue synergies by tripling
Slide 5: Counsyl's Portfolio of Women's Health Products
Counsyl’s Portfolio of Women’s Health Products Allows Entry Into High-Growth Reproductive Testing Market Expanded Carrier Screening Non-Invasive Prenatal Screening Hereditary Cancer Testing Clinical decision support for identifying inheritable disorders Clinical decision support for chromosome condi
Slide 6: Snapshot of Counsyl
Snapshot of Counsyl Rapidly Growing Diagnostic Business in Women’s Health Market Prelude NIPS 28% Reliant Hereditary Cancer 8% ForeSight ECS 64% Revenue Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.
Slide 7: Expanded Carrier Screening Market Opportunity
Expanded Carrier Screening Market Opportunity Multiple Opportunities for Growth Large, Expanding Market For ECS Limited Carrier Screening ≈500K tests Expanded Carrier Screening ≈400K tests No Carrier Screening 3.3M Tests + Partner Testing + Pre-Conception Testing ≈4.2 Million Pregnant Women Conversi
Slide 8: NIPS Market Expansion
NIPS Market Expansion Advancing Towards Standard of Care for All Women High Risk Average Risk >3x Market Growth Drivers Emerging Adoption in average-risk population as commercial payer coverage increases Continued Expansion in high-risk populations Copyright © 2018 Myriad Genetics, Inc., all rights
Slide 9: Rapid Growth Expected in Reproductive Testing Market
Rapid Growth Expected in Reproductive Testing Market 60% Increase in U.S. Test Volume Over Next Five Years U.S. Reproductive Testing Market 13% CAGR 9% CAGR 11% CAGR 16% CAGR Reproductive health market grows at low double-digit rate to 3.5M tests by FY23 U.S. Tests Performed Source: Counsyl, Public
Slide 10: Strategic Rationale 1+1=3
Strategic Rationale 1+1=3 Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com. Entry into high-growth reproductive testing market Comprehensive women’s health product offering Broad reimbursement with potential for future expansion Potential for revenue synergies by tripling
Slide 11: Strong Strategic Fit Within Strategy
Strong Strategic Fit Within Strategy Announcing Formation of Women’s Health Business Unit Risk? Diagnosis? Prognosis? Therapy? BIPOLAR * * Future potential product Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.
Slide 12: Comprehensive Women's Health Product Offering
Comprehensive Women’s Health Product Offering Best-in-Class Suite of Products Addressing >$5.0B U.S. Market Prospective Parents 4.2M patients per year $2.0B U.S. market opportunity Pregnant Women 4.2M patients per year $2.0B U.S. market opportunity Prospective Parents Adult Women >10M women in the U
Slide 13: Market Leading Expanded Carrier Screening Product
Market Leading Expanded Carrier Screening Product High-Growth Opportunity in $2.0B U.S. Market Expanded Carrier Screening (ECS): Testing for over 175 recessive genetic disorders in prospective parents to assess risk in future children Counsyl is the market leader with ≈20% market share Traditionally
Slide 14: Rapidly Gaining Market Share in NIPS Market
Rapidly Gaining Market Share in NIPS Market High-Growth Opportunity in $2.0B U.S. Market Non-Invasive Prenatal Screening: Testing for trisomies, sex chromosome disorders and microdeletions in a developing fetus using maternal blood Prelude growth has significantly exceeded the market growth rate and
Slide 15: Strategic Rationale 1+1=3
Strategic Rationale 1+1=3 Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com. Entry into high-growth reproductive testing market Comprehensive women’s health product offering Broad reimbursement with potential for future expansion Potential for revenue synergies by tripling
Slide 16: Guideline Support For ECS and NIPS Increasing
Guideline Support For ECS and NIPS Increasing Driving Expanded Reimbursement Coverage January 2015 March 2015 April 2015 March 2016 May 2016 July 2016 October 2016 April 2017 Any patient may choose cell-free DNA (cfDNA) analysis as a screening strategy for common aneuploidies regardless of her risk
Slide 17: Potential Reimbursement Catalysts
Potential Reimbursement Catalysts Several Opportunities to Expand Coverage With Prelude and Foresight Further guideline support for expanded carrier screening New ECS code at higher contracted ASP Further guideline support for average risk NIPS testing Average risk NIPS coverage expansion Medicaid c
Slide 18: Strategic Rationale 1+1=3
Strategic Rationale 1+1=3 Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com. Entry into high-growth reproductive testing market Comprehensive women’s health product offering Broad reimbursement with potential for future expansion Potential for revenue synergies by tripling
Slide 19: Significant Opportunity for Revenue Synergies
Significant Opportunity for Revenue Synergies Combined Sales Teams Will Triple Physician Reach in Women’s Health 225 Sales Reps 80 Sales Reps Largest genetics sales force in women’s health 3x physician reach for Counsyl’s tests Potential cross-selling opportunities in hereditary cancer 2x the size o
Slide 20: Strategic Rationale 1+1=3
Strategic Rationale 1+1=3 Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com. Entry into high-growth reproductive testing market Comprehensive women’s health product offering Broad reimbursement with potential for future expansion Potential for revenue synergies by tripling
Slide 21: Potential for Cost Synergies Through the Enterprise
Potential for Cost Synergies Through the Enterprise Experienced Integration Team Managing Project Same integration leadership with similar approach to the Assurex acquisition Leverage enterprise-wide functions such as R&D and Payer Markets Standardize informatics and IT platforms Leverage supplier p
Slide 22: Counsyl Software Tools Drive Ease of Use
Counsyl Software Tools Drive Ease of Use Potential to Leverage Core Competency in Informatics Workflow Solution for the Busy OB/GYN Innovative Process, Price and Information Transparency for Physicians and Patients PRE-TEST EDUCATION ORDERING COVERAGE & ESTIMATES RESULTS DELIVERY GENETIC COUNSELING
Slide 23: Strategic Rationale and Transaction Consideration
Myriad Genetics Acquisition of Counsyl, Inc. Strategic Rationale Entry into high-growth reproductive testing market Comprehensive women’s health product offering Broad reimbursement coverage with potential for further expansion Potential for revenue synergies by tripling reproductive testing reach P